Award
National Institute of Allergy and Infectious Diseases 11391667
Histoplasmosis Induction and Consolidation Therapy Factorial Randomized Clinical Trial (HISTO-FACT)
Recipient
University of Minnesota
Award Amount
$348,689.00
Ceiling
$348,689.00
Awarded
September 05, 2025
Identifier
11391667
NIH funds a phase III clinical trial led by the University of Minnesota to evaluate new therapies for histoplasmosis in HIV patients, focusing on safety and efficacy of specific treatments.
Description
A large phase III clinical trial funded by NIH to evaluate therapies for histoplasmosis in HIV patients. The project aims to assess safety and efficacy of high-dose liposomal amphotericin B, posaconazole, and shorter consolidation therapy duration. The project is led by the University of Minnesota and is part of NIH's efforts to improve treatment options for infectious diseases.